Related references
Note: Only part of the references are listed.Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis
Thomas E. Kraft et al.
MABS (2020)
An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans
Shan Chung et al.
MABS (2019)
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
Nicole M. Piche-Nicholas et al.
MABS (2018)
Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins
Shan Chung et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2018)
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Algirdas Grevys et al.
NATURE COMMUNICATIONS (2018)
Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms
Claudia A. Castro Jaramillo et al.
MABS (2017)
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development
Jing Wang et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2016)
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Lindsay B. Avery et al.
MABS (2016)
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics
Daniela Bumbaca Yadav et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Michal Pyzik et al.
JOURNAL OF IMMUNOLOGY (2015)
Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn
Tianlei Ying et al.
MABS (2015)
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
Amita Datta-Mannan et al.
MABS (2015)
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Colby A. Souders et al.
MABS (2015)
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Timo Rath et al.
CRITICAL REVIEWS IN BIOTECHNOLOGY (2015)
In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
Vikas K. Sharma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Tilman Schlothauer et al.
MABS (2013)
A strategy for risk mitigation of antibodies with fast clearance
Isidro Hoetzel et al.
MABS (2012)
Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned?
Rong Deng et al.
MABS (2011)
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Comparison of FcRn- and pIgR-Mediated Transport in MDCK Cells by Fluorescence Confocal Microscopy
Galina V. Jerdeva et al.
TRAFFIC (2010)
The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity
Salit Tzaban et al.
JOURNAL OF CELL BIOLOGY (2009)
Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice
Hector Perez Montoyo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism
Shreeram Akilesh et al.
JOURNAL OF IMMUNOLOGY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis
JC Zhou et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcγ-receptor
SM Claypool et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs
DC Roopenian et al.
JOURNAL OF IMMUNOLOGY (2003)
Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor
AP West et al.
BIOCHEMISTRY (2000)
Share Paper
